Efaproxiral
Alternative Names: EFAPROXYN; GSJ 61; JP 4; KDD 86; REVAPROXYN; RS 4; RSR 13Latest Information Update: 25 Sep 2021
At a glance
- Originator Center for Innovative Technology
- Developer Allos Therapeutics
- Class Aniline compounds; Antineoplastics; Propionic acids; Radiosensitisers; Small molecules
- Mechanism of Action Haemoglobin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Angina pectoris; Brain cancer; Cervical cancer; Glioblastoma; Glioma; Myocardial infarction; Non-small cell lung cancer; Stroke
Most Recent Events
- 19 Jun 2007 Discontinued - Phase-I/II for Cervical cancer in Canada (IV)
- 19 Jun 2007 Discontinued - Phase-I/II for Glioma in USA (IV)
- 19 Jun 2007 Discontinued - Phase-I/II for Non-small cell lung cancer in USA (IV)